Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Neurology & Psychiatry
Filter     Order     Display # 
Date Item Title
18 Jun 2008 Acurox(TM) Tablets Meet Primary Endpoint In Pivotal Phase III Study
17 Jun 2008 Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease
17 Jun 2008 Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
17 Jun 2008 Accentia Reports on Multiple Sclerosis Study: Revimmune(R) Shows Unprecedented Results in Reducing Disability and Improving Functions
17 Jun 2008 Takeda to Appeal EMEA Negative Opinion on ramelteon for the Treatment of Primary Insomnia
16 Jun 2008 ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial
16 Jun 2008 FDA Approves Cymbalta(R) for the Management of Fibromyalgia
16 Jun 2008 US FDA approves Requip(R) XL(TM), the first and only oral once-daily non-ergot dopamine agonist for Parkinson’s disease
16 Jun 2008 AZILECT(R) Market Potential Dramatically Increases, as the Drug Could Become the First Disease Modifying Treatment for Parkinson's Disease
16 Jun 2008 Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
12 Jun 2008 NOXXON Pharma AG Announces Licensing and Discovery Collaboration with Eli Lilly and Company
12 Jun 2008 Opexa Therapeutics Reports Favorable Two-Year Data in Phase I/II Retreatment Studies of Tovaxin(R) for Multiple Sclerosis
12 Jun 2008 Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
11 Jun 2008 EPIX Pharmaceuticals Initiates Second Trial in Phase 2b Program for Alzheimer's Disease
10 Jun 2008 AstraZeneca Submits Seroquel XR(TM) in Europe for the Treatment of Major Depressive Disorder
10 Jun 2008 Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
10 Jun 2008 Ambien CR(R) Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
10 Jun 2008 Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
10 Jun 2008 Synosia Begins Proof-of-Mechanism Trial For Nitisinone
10 Jun 2008 Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10 Jun 2008 Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
10 Jun 2008 Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease
10 Jun 2008 Targacept and AstraZeneca Initiate Clinical Trial of AZD3480 in Adult ADHD
10 Jun 2008 Javelin Pharmaceuticals Enrolls First Patient in Pivotal Trial for PMI-150
08 Jun 2008 Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
05 Jun 2008 Trophos completes enrolment of Phase II Clinical Trial of TRO19622 in painful peripheral diabetic neuropathy
04 Jun 2008 TorreyPines Therapeutics Initiates Clinical Trial to Evaluate
04 Jun 2008 Addex Starts Phase I ADX10059 Interaction Study
04 Jun 2008 Sciele Pharma Announces That Addrenex Has Completed Enrollment of Pivotal Phase III Trial for Clonicel for ADHD
03 Jun 2008 Mentor Announces Completion of Enrollment in Phase I Trial for Botulinum Toxin Type A in Patients with Cervical Dystonia
03 Jun 2008 Synosia Begins Phase IIa Trial For Potential First-in-Class Treatment for Parkinson’s Disease
03 Jun 2008 Acorda Therapeutics Announces Positive Data from Second Phase 3 Study of Fampridine-SR on Walking Ability in People with Multiple Sclerosis
29 May 2008 Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
29 May 2008 Trophos demonstrates analgesic activity of neuroprotective agent TRO19622 in preclinical models of painful peripheral neuropathy
29 May 2008 IntelGenx Corp. Today Announced Positive Results From a First Pilot Pharmacokinetic (PK) Study on the Anti-Depressant CPI-300
28 May 2008 Santhera Presents Efficacy Data of SNT-317 in Congenital Muscular Dystrophy at International Congress of Myology
28 May 2008 Galantos Pharma Receives Research Grant
28 May 2008 Stem Cell Therapeutics Corp. Announces Enrollment of the First Patient in its REGENESIS Phase IIb Stroke Trial
27 May 2008 AVANIR Announces Positive Outcome of Zenvia PK Study
26 May 2008 Extavia(R) approved in European Union for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis
23 May 2008 Allon completes dosing in Phase II cognitive impairment trial
22 May 2008 Lundbeck acquires European commercialization rights for Flurizan(R) from Myriad, USA - a new drug in final phase III development for the treatment of Alzheimer's disease
22 May 2008 QRxPharma Releases Additional Phase 3 Data for Q8003IR ‘Dual Opioid’ Pain Therapy
21 May 2008 FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
20 May 2008 KAI Pharmaceuticals Advances Third Product Candidate into Clinical Studies
16 May 2008 Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
15 May 2008 FDA Places Geron’s GRNOPC1 IND on Clinical Hold
15 May 2008 Orexo has submitted the registration application (NDA) for Sublinox (OX22) to the FDA on May 14 2008
14 May 2008 PRoFESS® results announced at XVII European Stroke Conference
14 May 2008 FDA Approves AstraZeneca’s Seroquel for Maintenance Treatment in Bipolar Disorder
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 201 - 250 of 1619

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics